Navigation Links
Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO)
Date:12/6/2010

DUBAI, United Arab Emirates, Dec. 6, 2010 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced data in five poster presentations relating to Cinryze® (C1 esterase inhibitor [human]) at the 2010 International Scientific Conference of the World Allergy Organization (WAO), December 5 through 8 in Dubai, UAE.  

This is the first international presentation of these data, which were first presented at the November 2010 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI).

Cinryze is the first and only U.S. FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease. Cinryze is currently available only in the United States.  Cinryze is not approved by the U.S. FDA to treat acute angioedema attacks, nor has the safety and effectiveness of Cinryze been established in pediatric patients with HAE.  Cinryze should be used in pregnant women only if clearly needed.

"These scientific posters mark the first international presentation of these important data which highlight the use of Cinryze across a range of patient populations," commented Glenn Tillotson, Ph.D., ViroPharma's head of US medical affairs.  "ViroPharma has been acknowledged as the U.S. leader in medical education about hereditary angioedema.  However, as we prepare to expand the usage of Cinryze to other parts of the world, it is essential that we broaden our focus, so that physicians around the globe are aware of the severity of disease, and the importance of Cinryze as an essential option for patients who want to gain control of their HAE attacks through prophylaxis, rather than relying purely on acute treatment to terminate their attacks once they have occurred.
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. ViroPharma Receives Complete Response Letter for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Supplement
2. ViroPharma Announces Publication of Cinryze™ (C1 Esterase Inhibitor [Human]) Phase 3 Trial Results in Hereditary Angioedema (HAE) in the New England Journal of Medicine
3. ViroPharma Files Prior Approval Supplement (PAS) for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Manufacturing
4. Hereditary Angioedema Patients Report: C1-Esterase Inhibitor Concentrate Effective in Treating Acute Attacks, Helps Them Avoid Emergency Care
5. PharmAthenes Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimers Disease
6. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
7. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
8. Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765
9. Portola Pharmaceuticals Announces Data Presentations Highlighting Syk/JAK Inhibitor Clinical Development Program at 52nd American Society of Hematology Annual Meeting
10. VIDEO from Merck and Co., Inc available on thenewsmarket.com: In Phase III Study Mercks Investigational CETP Inhibitor Anacetrapib Met Safety and Efficacy Endpoints in Patients with CHD
11. Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Avizia, Inc., a leading provider of cutting-edge ... equity financing round led by NextGen Angels along with ... will be used to continue to fuel the rapidly ... Edward Kennedy , CEO and president of Tollgrade ... Leonard Kurtzman , CFO of newBrandAnalytics, who joined the ...
(Date:8/19/2014)... MALVERN, Pa. , Aug. 19, 2014  SCILEX ... commercialization of late-stage pharmaceutical products for the treatment of ... composed of four members: Dr. Jeff Gudin , ... and Mr. Kip Vought . ... said the expertise of this board would greatly assist ...
(Date:8/19/2014)... Aug. 19, 2014 Luoxis Diagnostics, ... Inc. (NYSE MKT: AMPE), today announced an ... Meeting of the American Academy of Surgical Trauma ... in Philadelphia, Pennsylvania that ... will report results from a recently completed five-year ...
Breaking Medicine Technology:Avizia Closes Funding Round 2SCILEX Pharmaceuticals Announces Scientific Advisory Board 2SCILEX Pharmaceuticals Announces Scientific Advisory Board 3SCILEX Pharmaceuticals Announces Scientific Advisory Board 4Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting 2Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting 3
... Calif., Dec. 21 Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ... payment from OncoGenex Pharmaceuticals, Inc. (Nasdaq: OGXI ) ... Pharmaceutical Industries Ltd. ( TEVA). OGX-011 is a second-generation ... a successful Phase 2 program in patients with advanced prostate ...
... , SAN DIEGO, Dec. 18 LifeVantage Corporation ... Anti-Aging Cream, science-based solutions to oxidative stress, announced today that ... other parties, Zrii, LLC. Under the terms of this agreement, ... William Farley, on the one hand, and the Company and ...
Cached Medicine Technology:Isis Pharmaceuticals to Receive $10 Million From OncoGenex' License of OGX-011 to Teva 2Isis Pharmaceuticals to Receive $10 Million From OncoGenex' License of OGX-011 to Teva 3LifeVantage Announces Settlement of Zrii Litigation 2LifeVantage Announces Settlement of Zrii Litigation 3
(Date:8/20/2014)... Los Angeles, CA (PRWEB) August 20, 2014 ... specialization and a low availability of substitutes typify the ... buyer power score of 3.1 out of 5, indicating ... buyer power suggests buyers and suppliers have an equal ... research analyst Kayley Freshman-Caffrey. , First, few substitutes exist ...
(Date:8/20/2014)... August 20, 2014 First Choice ... emergency rooms in the United States, named Richard Daniels, ... FM 685 facility. , “We are pleased to ... director of our second facility in Pflugerville,” said Dr. ... Emergency Room. , Dr. Daniels received his undergraduate ...
(Date:8/20/2014)... 20, 2014 Kowa Optimed returns after ... to debut the new SL-17 portable slit lamp. , ... white LED source controlled by an illuminated thumb wheel ... SL-17 uses commercially available AAA rechargeable and dry cell ... design requiring batteries designed specifically for the device. The ...
(Date:8/20/2014)... August 20, 2014 This agreement ... of software defined networking, high availability cloud enablement, ... of Resellers, while allowing OPEN-V to sell storageFOUNDRY’s ... pleased to work with OPEN-V on this distribution ... Hows, manager distribution channels at storageFOUNDRY. "Nautilus is ...
(Date:8/19/2014)... 2014 Midtown Dentistry in Houston, Texas, is ... All patients with cavities, or with old fillings that ... that can safely repair and restore teeth. , From now ... materials, all of which are completely amalgam free. Even though ... by the FDA for adults and children over the age ...
Breaking Medicine News(10 mins):Health News:Packaging Design Services Procurement Category Market Research Report Now Available from IBISWorld 2Health News:Packaging Design Services Procurement Category Market Research Report Now Available from IBISWorld 3Health News:Packaging Design Services Procurement Category Market Research Report Now Available from IBISWorld 4Health News:First Choice Emergency Room Announces Dr. Richard Daniels as Medical Director of the Pflugerville – FM 685 Facility 2Health News:Kowa Optimed (Booth MS13043) to Debut New Portable Slit Lamp at 2014 Vision Expo West in Las Vegas, Nevada 2Health News:storageFOUNDRY and Open-V OzoneStack Announce Bilateral Distribution Agreement 2Health News:storageFOUNDRY and Open-V OzoneStack Announce Bilateral Distribution Agreement 3Health News:Midtown Dentistry Announces It Is Now an Amalgam-Free Office 2
... Health System set out to reduce energy consumption, they weren,t ... at healthcare facilities. Instead, they,re aiming for a 20 percent ... metric tons of carbon dioxide annually that,s not being released ... the road. The La Crosse, Wis.-based health system is on ...
... a statement by UNITE HERE General President Bruce Raynor:Contrary ... press contact, today,s General Executive Board meeting ended with ... President of UNITE HERE. To be crystal clear: I ... authorized Wilhelm to discuss this issue with me.(Logo: ...
... Only two percent of hospitals nationwide receive Magnet ... Center (ANCC) has announced that Baylor University ... earned re-designation as a Magnet hospital, effective immediately. ... been designated at a Magnet hospital, and merely ...
... Pharmos Corporation (Pink Sheets: PARS) announced today that ... and warrants. At the closing, the Company issued ... an additional 18,000,000 shares of common stock for an ... of the warrants, which have a five-year term, is ...
... 2009 (BRONX, NY) Recurrent and metastatic endometrial ... They have spread to other organs and typically have ... with chemotherapy may not be able to endure more ... of Yeshiva University have shown that a combination of ...
... Exposition Park LOS ANGELES, ... of Dimes premier fundraising event that benefits all babies--those born ... 11,000 walkers are expected at this largest March for Babies ... Park, at the corner of S. Figueroa and 39th St., ...
Cached Medicine News:Health News:Innovative Program Will Help Lead Health System to Energy Independence by 2014 2Health News:Statement From UNITE HERE General President Bruce Raynor on Today's General Executive Board Meeting 2Health News:Baylor Dallas Nationally Recognized for Nursing Excellence 2Health News:Pharmos Completes Private Placement - Raises $1.8 Million 2Health News:Pharmos Completes Private Placement - Raises $1.8 Million 3Health News:New treatment shows promise against recurrent gynecologic cancers 2Health News:Farmers Insurance Joins March of Dimes March for Babies April 25, 2009 2
IBT Reference Laboratory is a national research and specialty clinical lab founded in 1983 that provides a wide range of tests and services in the area of allergy, clinical immunology and molecular b...
Marquette General Health System Reference Laboratory provides a full range of testing including, Chemistry, Hematology, Coagulation, Urinalysis, Microbiology, Cytology, Anatomic Pathology, Flow Cytom...
Headquartered in Burlington, North Carolina, LabCorp has more than 23,500 employees and offers more than 4,400 clinical tests ranging from routine blood analyses to the most sophisticated molecular d...
the LabOne Healthcare Group markets laboratory testing to physicians, patients, managed care companies, self-insured employers, wellness companies and hospitals....
Medicine Products: